Register to chat with like-minded investors on our interactive forums.
Period:
Draw Mode:
| Volume | 0 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Xencor Inc | XNCR | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 20.11 | 20:00:00 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 20.11 |
| Trades | Volume | Avg Volume | 52 Week Range |
|---|---|---|---|
| 0 | 0 | - | 16.49 - 30.21 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| - | 0 | $ 20.11 | USD |
Xencor Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 1.23B | 61.12M | - | 168.34M | -126.09M | -2.06 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Xencor News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical XNCR Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 21.27 | 22.11 | 19.78 | 20.53 | 628,335 | -1.16 | -5.45% |
| 1 Month | 22.22 | 23.52 | 19.78 | 21.53 | 505,152 | -2.11 | -9.50% |
| 3 Months | 20.41 | 26.84 | 18.26 | 22.05 | 724,015 | -0.30 | -1.47% |
| 6 Months | 18.85 | 26.84 | 16.49 | 21.01 | 612,474 | 1.26 | 6.68% |
| 1 Year | 29.41 | 30.21 | 16.49 | 22.03 | 466,338 | -9.30 | -31.62% |
| 3 Years | 45.20 | 45.21 | 16.49 | 27.05 | 359,237 | -25.09 | -55.51% |
| 5 Years | 32.84 | 58.345 | 16.49 | 30.99 | 356,956 | -12.73 | -38.76% |
Xencor Description
| Xencor Inc is a clinical-stage biopharmaceutical company based in the United States. It focuses on discovering and developing engineered monoclonal antibody and other protein therapeutics to treat severe and life-threatening diseases with unmet medical needs. The company uses its XmAb technology platform to create antibody product candidates such as XmAb5871 and XmAb7195. It also has a few pre-clinical stage candidates in its portfolio such as XmAb14045 and XmAb13676. It earns its revenue from research and development collaborations and licenses of its internally developed drug candidates. |
